Abstract Hemangiosarcoma (HSA), a locally invasive and highly metastatic endothelial cell neoplasm, accounts for two-thirds of all cardiac and splenic neoplasms in dogs. Bartonella spp. infection has been reported in association with neoplastic and non-neoplastic vasoproliferative lesions in animals and humans. The objective of this study was to determine the prevalence of Bartonella spp. in conjunction with two other hemotropic pathogens, Babesia spp. and hemotropic Mycoplasma spp., in tissues and blood samples from 110 dogs with histopathologically diagnosed HSA from throughout the United States. This was a retrospective, observational study using clinical specimens from 110 dogs with HSA banked by the biospecimen repository of the Canine Comparative Oncology and Genomics Consortium. Samples provided for this study from each dog included: fresh frozen HSA tumor tissue (available from n = 100 of the 110 dogs), fresh frozen non-tumor tissue (n = 104), and whole blood and serum samples (n = 108 and 107 respectively). Blood and tissues were tested by qPCR for Bartonella, hemotropic Mycoplasma, and Babesia spp. DNA; serum was tested for Bartonella spp. antibodies. Bartonella spp. DNA was amplified and sequenced from 73% of dogs with HSA (80/110). In contrast, hemotropic Mycoplasma spp. DNA was amplified from a significantly smaller proportion (5%, p<0.0001) and Babesia spp. DNA was not amplified from any dog. Of the 100 HSA tumor samples submitted, 34% were Bartonella PCR positive (32% of splenic tumors, 57% of cardiac tumors, and 17% of other tumor locations). Of 104 non-tumor tissues, 63% were Bartonella PCR positive (56% of spleen samples, 93% of cardiac samples, and 63% of skin/subcutaneous samples). Of dogs with Bartonella positive HSA tumor, 76% were also positive in non-tumor tissue. Bartonella spp. DNA was not PCR amplified from whole blood. This study documented a high prevalence of Bartonella spp. DNA in dogs with HSA from geographically diverse regions of the United States. While 73% of all tissue samples from these dogs were PCR positive for Bartonella DNA, none of the blood samples were, indicating that whole blood samples do not reflect tissue presence of this pathogen. Future studies are needed to further investigate the role of Bartonella spp. in the development of HSA.

Citation: Lashnits E, Neupane P, Bradley JM, Richardson T, Thomas R, Linder KE, et al. (2020) Molecular prevalence of Bartonella, Babesia, and hemotropic Mycoplasma species in dogs with hemangiosarcoma from across the United States. PLoS ONE 15(1): e0227234. https://doi.org/10.1371/journal.pone.0227234 Editor: Douglas H. Thamm, Colorado State University, UNITED STATES Received: October 3, 2019; Accepted: December 13, 2019; Published: January 10, 2020 Copyright: © 2020 Lashnits et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: All relevant data are available from Dryad at https://doi.org/10.5061/dryad.ttdz08ktd. Funding: This research was supported by the American Kennel Club Canine Health Foundation (CHF Grant No. 2550, EBB and MB, http://www.akcchf.org/) and the State of North Carolina. EL’s research is supported in part by the Comparative Medicine and Translational Research Program of the National Institutes of Health under award number T32OD011130. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: In conjunction with Dr. Sushama Sontakke and North Carolina State University, Edward B. Breitschwerdt, DVM holds U.S. Patent No. 7,115,385: “Media and Methods for Cultivation of Microorganisms”, which was issued October 3, 2006. He is a co-founder, shareholder and Chief Scientific Officer for Galaxy Diagnostics, a company that provides advanced diagnostic testing for the detection of Bartonella species infections. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors declare no potential conflicts of interest.

Introduction There are clear precedents for the involvement of bacterial infection in neoplastic development. Within the past 25 years, a considerable volume of research has been conducted on the oncogenic properties of infectious agents such as bacteria, mycoplasma, protozoa, and viruses.[1,2] Currently, infectious agents are accepted as a cause or co-factor in anywhere from 5–50% of human cancers worldwide, depending on the geographic region and its development status.[1–3] The involvement of infectious agents in the pathogenesis of some human cancers is therefore well established. The majority of infectious agents implicated in oncogenesis are viruses, such as Epstein Barr virus, human papillomaviruses, and Kaposi’s sarcoma-associated herpesvirus.[1] These viruses have direct oncogenic properties through integration of viral genomes into host cells, or by secretion of gene products into healthy cells to create tumor cells. The extent to which other infectious agents, such as bacteria, lack the inherent oncogenic properties of their viral counterparts remains unclear. Bacteria most often promote cancer development indirectly through persistent replication, inflammation and chronic tissue damage.[4,5] Helicobacter pylori, for example, colonizes and replicates within the gastric mucosa, resulting in a chronic pro-inflammatory response that promotes cancer risk and oncogenesis of gastric cancer by altering epithelial cell proliferation and apoptosis.[6] With the difficulty of assessing causality, particularly for certain rare cancer types, there may be roles for other pathogenic bacteria in a range of different cancers that have not yet been discovered.[7] Hemangiosarcoma (HSA) is a highly aggressive endothelial cell cancer that is associated with local invasiveness and a high metastatic potential in dogs (Fig 1).[8,9] The most common neoplasm of the spleen,[10] this cancer is found in up to 2% of all dogs with tissues submitted for autopsy.[11] While HSA may affect any dog breed, several of the most popular family owned pure breeds are highly predisposed, including the golden retriever, Labrador retriever and German Shepherd Dog.[12–14] Splenic HSA is among the most common canine cancers encountered in clinical practice, accounting for approximately two thirds of all splenic tumors (neoplasms of the spleen, benign or malignant, comprise approximately half of all splenic pathology in dogs).[9] Cardiac HSA is less common than splenic HSA (most studies reporting less than 1% of all canine neoplasms), but remains the most common cardiac tumor of dogs.[15,16] Other primary tumor locations such as the liver and skin are reported, but rare. PPT PowerPoint slide

PowerPoint slide PNG larger image

larger image TIFF original image Download: Fig 1. Images of hemangiosarcoma (HSA) tumors from dogs. A) Primary HSA mass in a spleen. B) Metastatic HSA in a liver with multifocal masses in all lobes. C) Metastatic hemangiosarcoma in the lungs with multifocal masses in all lobes. D) Photomicrograph of a splenic HSA from a dog in the current study that was PCR positive for B. henselae. 20X magnification. Hematoxylin and eosin. Credits: Talley A (image A), Sommer S (image B), Rasche B (image C) and Barnes J (image D). https://doi.org/10.1371/journal.pone.0227234.g001 Splenic HSA is often difficult to diagnose without resorting to splenectomy, a major invasive abdominal surgery.[8,17] Moreover, as an indolent disease, malignant HSA masses that develop within the abdominal cavity often remain undetected until reaching an advanced stage, at which time there is a high risk of spontaneous rupture potentially leading to untreatable and ultimately fatal internal hemorrhage.[18] Because of this risk, as well as the lack of broadly effective chemotherapeutics, the prognosis is poor. The median survival after diagnosis ranges from less than 3 weeks with splenectomy surgery alone to six months with surgery plus cancer chemotherapy.[19,20] As a result there is a critical need for improved diagnostic modalities for earlier detection of HSA, as well as new treatments and preventative strategies to improve outcomes for this common tumor of family pets. Despite substantial research, the etiology and pathogenesis of canine HSA remains unclear. As a malignant tumor of vascular endothelial cells, factors that have been hypothesized to contribute to the pathogenesis of HSA include chronic inflammation, macrophage activation, hypoxia, and angiogenesis.[21] In vitro, HSA cells produce growth factors promoting angiogenesis, including vascular endothelial growth factor-A (VEGF-A), platelet-derived growth factor-β (PDGF-β), and basic fibroblast growth factor (bFGF), and genes involved in inflammation, angiogenesis, and cellular adhesion and invasion can distinguish HSA cells from non-malignant endothelial cells.[9,21] Because of established links between chronic intracellular infections, inflammation, and angiogenesis, efforts are being made to determine if chronic intravascular infection with bacteria or protozoa could contribute to HSA development in dogs. One previous study from our laboratory examined the molecular prevalence of blood (erythrocyte)-borne pathogens in a small cohort of dogs from the southeastern United States with and without splenic pathology.[22] We found that Bartonella spp. were significantly more common than Babesia spp. or hemotropic Mycoplasma spp. in formalin-fixed, paraffin embedded biopsy samples from splenic HSA: 26% of dogs were positive for Bartonella spp. compared to 2% for Babesia spp. (p < 0.001) and 6% for hemotropic Mycoplasma spp. (p = 0.006). Moreover, Bartonella spp. were found more often in splenic HSA biopsy samples compared to samples from a non-neoplastic inflammatory disorder of the spleen (lymphoid nodular hyperplasia, LNH) and histologically normal splenic tissue from specific-pathogen-free dogs.[22] We have subsequently documented that Bartonella spp. DNA can be amplified from angioproliferative lesions in cats, cows, dogs and horses.[23] In addition, it has been demonstrated that multiple Bartonella spp. (B. bacilliformis, B. quintana, B. henselae, and three Bartonella vinsonii subsp. berkhoffii genotypes) can induce the in vitro production of VEGF.[23–25] Bartonella spp. can cause endothelial proliferative disorders, including bacillary angiomatosis and peliosis hepatis, in dogs and humans.[26–31] In combination, these observations suggest the potential for involvement of intra-erythrocytic and endotheliotropic Bartonella spp. in the initiation and/or progression of vascular endothelial neoplasia in dogs. However, in our previous case control study demonstrating an association between Bartonella spp. infection and HSA,[22] samples were restricted to a single geographical region (North Carolina) and a single anatomical site (splenic HSA). Seroprevalence studies show that Bartonella spp. exposure in dogs can be seen throughout the United States, and there are relatively small but statistically significant regional differences in seroprevalence.[32,33] Additionally, the presence of Bartonella spp. DNA in splenic tissue could potentially by explained by the spleen’s role in removal of hemotropic parasites from systemic circulation, or by Bartonella spp. bacteremia at the time of splenic specimen collection. To address these outstanding questions, this study sought to further clarify the potential involvement of Bartonella spp. in HSA in a broader anatomic and geographic context. The objective of this study was to determine the prevalence of Bartonella spp. in conjunction with two other hemotropic pathogens, Babesia spp. and hemotropic Mycoplasma spp., in tissues and blood samples from dogs with histopathologically diagnosed HSA from throughout the United States. Our hypotheses were: 1) the prevalence of Bartonella spp. infection in dogs with HSA would be greater than the prevalence of Babesia or hemotropic Mycoplasma spp., and 2) the prevalence of Bartonella spp. infection in dogs with HSA in the spleen will be similar to prevalence in dogs with HSA in other anatomic locations, such as cardiac muscle.

Methods Study design and sample sources This was a retrospective, observational, descriptive study of 110 dogs with HSA. Specimens used for this study were previously collected and banked by the Canine Comparative Oncology and Genomics Consortium (CCOGC) based on previously published standard operating procedures.[34]. Briefly, the CCOGC collected samples from eight participating veterinary university teaching hospitals starting in 2006 with the goal of creating a repository of clinical samples from dogs with common naturally occurring cancers. Prior to sample submission to CCOGC, dogs were given a definitive diagnosis of neoplasia based on histopathology performed by a board-certified veterinary pathologist at the diagnostic laboratory of each participating university. Tissue samples for the CCOGC biospecimen repository were obtained from the primary tumor via surgical biopsy or post-mortem collection (HSA tumor tissue). As an internal control, tissue samples from each dog were also obtained from adjacent grossly normal tissue in the same organ, or if no grossly normal tissue in the affected organ was apparent, skin biopsies were obtained (non-tumor tissue). Tissue submission (HSA tumor and non-tumor) from each dog required provision of both formalin-fixed (subsequently stored in ethanol) and non-fixed specimens snap-frozen in liquid nitrogen (subsequently stored at -80° C). Dogs also had serum and whole blood collected at the time of tissue sampling for submission to the CCOGC. For this study, samples from dogs diagnosed with HSA were provided by the CCOGC repository to the investigators. Four sample types were provided for pathogen testing: fresh frozen HSA tumor tissue, fresh frozen non-tumor tissue, whole blood, and serum. Two sample types were provided for histopathological confirmation of tissue type and tumor presence included: formalin-fixed HSA tumor tissue and formalin-fixed non-tumor tissue. Any dog that had a diagnosis of HSA (as determined by the CCOGC SOP), and had an adequate amount of fresh frozen tissue stored in the biorepository at the time of the investigators’ request for specimens, was included. This study, therefore, included 110 dogs with samples collected between May 2008 and November 2011. Because of previous sample requests or lack of submission of all requested samples to the CCOGC, there were samples missing when provided to the investigators. Of the 110 dogs, 91 had a complete set of the 4 sample types for pathogen testing (fresh frozen HSA tumor tissue, fresh frozen non-tumor tissue, whole blood, serum) provided to the investigators. No dog was missing more than one sample type, and all dogs had at least one fresh-frozen tissue sample (HSA tumor, non-tumor tissue, or both) available for testing. For this reason, dogs with missing samples for pathogen testing were not excluded from the study. Similarly, of the 110 dogs only 37 had a complete set of the 2 sample types for histopathological confirmation (formalin-fixed HSA tumor tissue, formalin-fixed non-tumor tissue) provided to the investigators. Of the 110 dogs, 37 had formalin-fixed HSA tumor tissue and 93 had formalin-fixed non-tumor tissue provided. There were no formalin-fixed samples of HSA tumor or non-tumor tissue from cardiac tumors available for independent histopathologic review. Because a large proportion of dogs were missing formalin-fixed samples for independent histopathological confirmation, the subgroups of tissues with independent histopathologic confirmation of tissue type and tumor presence was analyzed separately. The CCOGC provided demographic information for each dog, including age (years), breed, weight (kg) and sex and neuter status. The date and geographic location (university teaching hospital) of sample collection was also provided. The anatomic location of tumor and non-tumor tissue samples for each dog was also provided. Independent confirmation of demographic and histologic data When possible, information provided by the CCOGC was independently confirmed by the investigators for this study. Histopathology reports providing the diagnosis of hemangiosarcoma were provided for 102 dogs; these were reviewed by one author (EL) to confirm hemangiosarcoma diagnosis and tumor location. For dogs with formalin-fixed biopsy samples provided (see above), biopsies were independently evaluated by a board-certified veterinary pathologist (KL) to confirm the tissue and tumor origin of the biopsy. Formalin fixed tissues were submitted to the NCSU College of Veterinary Medicine histology laboratory (Raleigh NC) and tissues were embedded in paraffin blocks (FFPE blocks). Slides containing 5 um sections were prepared from the FFPE blocks and stained with hematoxylin and eosin (H&E). Samples were categorized by organ type and HSA tumor or non-tumor tissue based on H&E staining. If the tissue of origin was not able to be determined from the biopsy (5 tumor samples and 2 non-tumor tissues), or if no formalin-fixed sample was provided (68 tumor samples and 14 non-tumor tissues), the tissue of origin was categorized by the information provided by the CCOGC and the original diagnostic histopathology reports. Non-tumor tissues from skin or various subcutaneous tissues (including hair, skin, adipose, skeletal muscle, or mammary gland, or any combination of these tissues) were categorized as skin/SQ for analysis. Pathogen detection methods DNA was extracted from EDTA anti-coagulated blood and fresh frozen tissue samples using a Qiagen DNeasy® Blood and Tissue kit (Qiagen, Valencia, CA) following the manufacturer’s protocols. For each tissue sample (HSA tumor and non-tumor), a 25 mg piece of tissue was excised from the entire sample using a new, prepackaged sterile scalpel. DNA yield and quality was assessed by spectrophotometry (Nanodrop, Wilmington, DE). Each DNA sample was screened for the presence of Bartonella spp. DNA using conventional and qPCR, and Babesia spp. and hemotropic Mycoplasma spp. using qPCR. Bartonella qPCR was performed using primers targeting the 16S-23S intragenic transcribed spacer (ITS) region of Bartonella species as described previously[35], in conjunction with a BsppITS438 FAM-labeled hydrolysis probe (TaqMan, Applied Biosystems, Foster City, CA, USA). Bartonella qPCR was performed at two dilutions for each sample (using 1 uL and 5 uL of template DNA respectively). PCR screening for Babesia spp. and hemotropic Mycoplasma spp. were carried out as described previously.[22] Briefly, oligonucleotides Myco16S-322s (5’ GCCCATATTCCTACGGGAAGCAGCAGT 3’) and Myco16S-938as (5’ CTCCACCACTTGTTCAGGTCCCCGTC 3’) were used as forward and reverse primers respectively for hemotropic Mycoplasma spp. DNA amplification. Oligonucleotides Piro18S-144s (5’ GATAACCGTGSTAATTSTAGGGCTAATACATG 3’) and Piroplasma18S-722as (5’ GAATGCCCCCAACCGTTCCTATTAAC 3’) were used as forward and reverse primers respectively for Babesia spp. DNA amplification. Amplification was performed in a 25-μl final volume reaction containing 12.5 μl of MyTaq Premix (Bioline), 0.2 μl of 100 μM of each forward primer, reverse primer (IDT® DNA Technology), 7.1 μl of molecular–grade water, and 5 μl of DNA from each sample tested. PCR negative controls were prepared using 5 μl of DNA from blood of a healthy dog. Positive controls for PCR were prepared by using 5 μl of DNA from previously characterized positive dog (clinical cases). Conventional PCR was performed in an Eppendorf Mastercycler EPgradient® under the following conditions: a single hot-start cycle at 95°C for 2 minutes followed by 55 cycles of denaturing at 94°C for 15 seconds, annealing at 68°C for 15 seconds, and extension at 72°C for 18 seconds. Amplification was completed by an additional cycle at 72°C for 1 minute, and products were analyzed by 2% agarose gel electrophoresis with detection using ethidium bromide under ultraviolet light. Validation of positive results was performed by Sanger sequencing of amplicons followed by chromatogram evaluation and sequence alignment using Contig-Express and Align X software (Vector NTI Suite 10.1, Invitrogen Corp, CA, USA). For bacterial species identification, DNA sequences were analyzed for nucleotide sequence homology at NCBI nucleotide database using BLAST version 2.0. A sample was considered Bartonella spp. PCR positive if one or more PCR tests (qPCR or conventional PCR) were positive (tests run in parallel). Stringent processing methods were used to avoid DNA carryover during tissue processing.[36] Specifically, tissue samples were processed independently using manual DNA extraction. For all batches of DNA extractions, between 2 and 4 blanks samples (water) were used as negative controls. All negative controls for DNA extractions rendered negative results on all PCR assays. DNA carryover after PCR amplification was avoided by processing each sample in three separate laboratory rooms (one for sample sorting and DNA extraction, a second for PCR processing, and a third for PCR analysis post amplification), and strict use of personal protective equipment for sample handling by laboratory personnel. For IFA testing, Bartonella antibodies were determined using 3 cell culture grown Bartonella spp. (Bartonella henselae, Bartonella vinsonii subsp. berkhoffii, and Bartonella koehlerae) as antigens and following standard immunofluorescent antibody assay (IFA) techniques.[37,38] Briefly, bacterial colony isolates were passed from agar plate grown cultures into permissive cell lines. For each antigen, heavily infected cell cultures were spotted onto 30-well Teflon-coated slides (Cel-Line/Thermo Scientific), air-dried, acetone-fixed, and stored frozen. Fluorescein conjugated goat anti-dog IgG (KPL, SeraCare, Milford MA) was used to detect bacteria within cells using a fluorescent microscope (Carl Zeiss Microscopy, LLC, Thornwood NY). Serum samples were diluted in phosphate-buffered saline (PBS) solution containing normal goat serum, Tween-20, and powdered nonfat dry milk to block nonspecific antigen binding sites. Sera were first screened at dilutions of 1:16 to 1:64. All sera that are reactive at 1:64 were further tested with two-fold dilutions to 1:8192. Study size An initial power calculation was based on a request for samples from 150 HSA cases from the CCOGC. With 150 HSA cases, assuming the prevalence of Bartonella PCR positive cases reported previously in dogs with HSA,[22] using an alpha of 0.05 this study would have 80% power to detect a difference in the prevalence of Bartonella spp. DNA in canine cardiac vs. splenic HSA (assuming samples were split evenly between the two tumor locations) if 49% or more, or 7% or less of the cardiac samples were Bartonella PCR positive. In addition, assuming the prevalence of each hemotropic pathogen reported previously in dogs with HSA,[22] using an alpha of 0.05 this study would have 80% power to detect similar size differences with 124 cases for hemotropic Mycoplasma and 80 cases for Babesia spp. Statistical methods Descriptive statistics were obtained for demographic factors (age, weight, sex, breed, season of sample collection, geographic location). We assessed statistical differences in the proportion of dogs PCR positive for each hemotropic pathogen using the Chi-squared test of independence (or Fisher’s exact tests for small sample numbers). We also assessed statistical differences in the proportion of samples PCR positive from each anatomic location using the Chi-squared test of independence (or Fisher’s exact tests for small sample numbers). Differences between demographic factors for Bartonella PCR positive and negative dogs were determined using the Wilcoxon Rank-Sum test for continuous variables (age, weight), and Fisher’s exact tests for categorical variables. Multivariable logistic regression was used to identify associations between Bartonella infection and anatomic location of tissue sample, with potential demographic confounders included as explanatory variables (age, weight, sex, breed, season of sample collection, and geographic location of sample collection). Odds ratios (adjusted ORs) and 95% confidence intervals (95% CIs) were calculated. To determine agreement between tests on two different samples within the same dog, the kappa statistic was calculated.[39] Data analysis was performed using R 3.6.0 (https://www.R-project.org/).

Discussion Overall, in this study 73% of dogs with HSA were Bartonella spp. PCR positive on HSA tumor tissue, non-tumor tissue, or bothtissue samples. Consistent with our previous study,[22] the proportion of Bartonella spp. infection in dogs with HSA was significantly greater than the proportion of Babesia or hemotropic Mycoplasma spp. Somewhat surprisingly, Bartonella spp. DNA was amplified more often from non-tumor tissues (63%) compared to HSA tumors tissues (34%). There are several potential explanations for the difference in Bartonella prevalence between HSA tumor and non-tumor tissues. It is possible that in large vascular splenic tumors there are necrotic or infarcted regions that contain fewer organisms, placing these samples below the level of PCR detection. This possibility is supported by amplification of Bartonella spp. DNA from 75% of non-tumor tissues obtained from the 32 dogs that were PCR positive from their HSA tumors. It is also possible that the high prevalence of Bartonella DNA in non-tumor tissues reflects asymptomatic carriage and is not associated with HSA. However since all 110 dogs had HSA, the higher prevalence in non-tumor tissue does not necessarily contradict the hypothesis that Bartonella infection is associated with HSA–rather, in the absence of a control group of dogs without HSA, we cannot conclude whether this high prevalence is seen in the absence of HSA as well. Further studies using a case-control or cohort design to compare Bartonella spp. PCR prevalence between dogs with HSA and without HSA will be needed to determine if this is the case. While the proportion of dogs with Bartonella spp. DNA in one or more tissue samples was surprisingly high, no dog had Bartonella DNA amplified from a blood sample. This suggests that Bartonella DNA found in any given tissue is not due to blood contamination of the tissue, but rather that the Bartonella may be intracellularly localized within that tissue. Similar results have been reported previously: in one case dogs experimentally infected with Bartonella spp. failed to become detectably bacteremic, despite Bartonella spp. being isolated from tissues (bone marrow and lung) post-mortem; in another, a dog had B. henselae DNA amplified from biopsies of vasculitis lesions and normal skin, but no Bartonella DNA on multiple sequential blood samples.[40,41] Reasons that Bartonella DNA is not found in blood samples from dogs with Bartonella present in tissue could include intermittent bacteremia, rapid clearance of bacteremia by the dogs’ immune system, or low levels of bacteremia that are below the current limit of PCR detection. Regardless, Bartonella blood PCR does not effectively predict whether a dog is infected with a Bartonella spp. Similarly, Bartonella spp. serology was also positive in only a small fraction of those dogs with positive Bartonella spp. PCR in tissue. Previous results documenting poor agreement between Bartonella spp. exposure based on IFA, and Bartonella spp. bacteremia in dogs have been reported.[42,43] Finally, in comparison with FFPE splenic HSA tumors tested for Bartonella in our previous study, Bartonella testing on fresh-frozen splenic HSA tumors yielded very slightly higher levels of detection (26% of fixed tissue vs. 28–32% of fresh frozen tissue). Based upon this study, we recommend that when possible, fresh frozen tissue biopsies from either the affected organ, or unaffected skin, be collected and submitted for PCR testing to maximize the potential for detection of Bartonella spp. Future studies will be needed to guide medical decision making when Bartonella spp. infection is documented in a dog with HSA. To address the possibility that Bartonella spp. DNA is found in high proportions of dogs’ spleens due to the spleen’s role in immunologic clearance of bacteria or infected erythrocytes from circulation, we tested multiple other organs for the presence of Bartonella DNA. Rather than seeing the highest proportions of splenic tissue positive for Bartonella DNA, in both tumor and non-tumor tissues we found cardiac tissues to have a higher proportion positive. This may reflect a tissue tropism of Bartonella for cardiac tissue, which would be compatible with the known ability of Bartonella to infect heart valves as a cause of endocarditis (or less commonly, myocarditis).[44–47] Additionally, when examining non-tumor tissues, we found a similar proportion of skin/SQ samples were positive for Bartonella compared to spleen samples. This may reflect an alternative tissue tropism for the bacteria, which is vector-borne and relies on the bite of an arthropod vector for transmission. Establishing latent infection in the skin could be an evolutionary response to enhance the likelihood of uptake during blood feeding by arthropod vectors. Based on the results presented here, it is unlikely that the high proportion of dog spleen samples positive for Bartonella spp. DNA on PCR reflect solely splenic clearance of bacteria or infected erythrocytes. Because of the surprisingly high proportion of dogs with HSA with Bartonella DNA in tissue samples in this study, and the well-established ability of Bartonella spp. to induce angiogenesis and chronic inflammation in vivo and in vitro, we speculate that B. henselae could be a cause or cofactor in the development of HSA in dogs. Angiogenesis is a fundamental component of primary tumor cell proliferation and metastasis, particularly in HSA.[21,48–52] Specifically, dogs with HSA have increased amounts of plasma VEGF compared to healthy dogs,[48] VEGF and its receptors are present in tumors (when evaluated with IHC)[52] and upregulated in HSA compared to benign hemangioma[49] (and in xenograft tumors using a mouse model)[50]. In vitro, B. henselae induces angiogenesis and proliferation of endothelial cells in part by stimulating production of VEGF.[23–25,31,53,54] It is well established that Bartonella spp. cause the non-neoplastic endothelial proliferative disorders bacillary angiomatosis and peliosis hepatis in humans, and there have also been rare reports of these conditions in dogs infected with Bartonella spp.[26–31,53,55,56] In addition, there have been case reports documenting neoplastic endothelial cell tumors in humans and dogs infected with Bartonella spp.: B. vinsonii subsp. berkhoffii was isolated from a dog with hemangiopericytoma, and from humans residing on three continents with epithelioid hemangioendothelioma.[57,58] The high prevalence of Bartonella DNA in tissues from dogs with HSA supports the need for further studies on the mechanistic basis of a potential link between Bartonella spp. infection and vascular endothelial cancers like HSA. Limitations of this study include the use of archived specimens, which precluded systematic sampling from particular organs of interest. This study was designed to be descriptive, and as such there was no control group consisting of dogs without HSA. Because of the lack of control group in this study, we cannot determine whether Bartonella spp. infection is epidemiologically associated with HSA. Additionally, only approximately one third of tumor tissue samples were able to be independently reviewed to confirm their anatomic tissue of origin and that they contained neoplastic cells. However, the overall pattern of lower Bartonella DNA prevalence in HSA tumor tissue compared to non-tumor tissue that was evident in both the spleen and cardiac tissues was also present in the subgroup of splenic tissues that did have independent histopathologic confirmation of anatomic location and tumor cell presence. There was not fixed tissue provided for independent histopathologic review from any of the cardiac samples (tumor or non-tumor), so diagnosis relied on the histopathologic reports from the submitting veterinary colleges. This may have led to misclassification of cardiac tissues as tumor or non-tumor. However due to the biological behavior of HSA in the heart, with most tumors presenting as a mass involving the right atrium (even in dogs with concurrent splenic HSA), correct classification of tissue as HSA (mass in right atrium) or non-tumor (other unaffected cardiac tissue) at the time of sample collection was assumed to be accurate. This study was also limited by using IFA to detect Bartonella spp. antibodies. IFA is known to have low sensitivity and may underestimate the true seroprevalence of Bartonella spp. in dogs.[42,59–62] The use of other serological assays currently under development, such as Western Blot or ELISA, may improve sensitivity of detection of seroreactivity. Finally, the initial power calculations for determining a statistically significant difference in Bartonella infection of tumors from different anatomic locations (splenic vs. cardiac) was based on 75 splenic and 75 cardiac cases. In fact, we received many fewer cardiac samples than expected, which decreased the power of this aim of the study. With the sample size used (69 splenic and 13 cardiac), the study was underpowered to detect the empiric difference that was found (33% Bartonella PCR positive for splenic and 54% for cardiac). In contrast, because all 105 dogs were able to be tested for each pathogen, despite the slightly smaller sample size than expected this aim was adequately powered to detect the empiric differences found (74% Bartonella spp. PCR positive, 3% hemotropic Mycoplasma PCR positive, 0% Babesia spp. PCR positive). We conclude that our findings strengthen the need to further investigate the role of Bartonella in the development of HSA, particularly with well controlled epidemiologic studies and mechanistic research to identify how this genus may contribute to tumor development. Ultimately, the development of a vaccine to protect dogs against Bartonella infection could potentially decrease the prevalence of this highly malignant neoplasm.